IART
Integra LifeSciences Holdings Corporation
IART offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over IART overall, supported by stronger valuation and stronger modeled upside.
IART Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Under pressure |
IART's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
IART PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 6.2x | $14.35 | — |
| Cheap | 26x | $4.14 | -71% |
| Fair | 34x | $5.42 | -62% |
| Expensive | 84x | $13.36 | -6.9% |
| Current | 90x | $14.35 | — |
Historical ranges are pointers, not guarantees.
IART's PE is in its expensive range at 90x. On analysts' estimates for next year's earnings, today's price would be 6.2x, in its cheap range.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH has the edge over IART in the historical PE scenario, which offers more potential upside but is not a forecast.
IART Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect IART's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
UNH has the edge over IART on the outlook, with more favorable earnings and profitability expectations.
IART Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.33 | +1357% |
| Q3 2026 | $0.16 | +$6.62 |
| Q2 2026 | -$0.10 | +$6.43 |
| Q1 2026 | -$6.47 | -$6.09 |
| Q4 2025 | -$6.74 | -$6.65 |
| Q3 2025 | -$6.46 | -$6.38 |
| Q2 2025 | -$6.53 | -2277% |
| Q1 2025 | -$0.38 | -175% |
| Q4 2024 | -$0.09 | -111% |
IART has returned to profit: it earned $0.16 per share over the past year, after losing money the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over IART on earnings, with more consistent year-over-year improvement.
IART Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $411.2M | +2.3% |
| Q2 2026 | $418.8M | +0.8% |
| Q1 2026 | $391.9M | +2.4% |
| Q4 2025 | $434.9M | -1.7% |
| Q3 2025 | $402.1M | +5.6% |
| Q2 2025 | $415.6M | -0.6% |
| Q1 2025 | $382.7M | +3.7% |
| Q4 2024 | $442.6M | +11% |
IART's revenue grew through 2021 and has held roughly level since: $411M last quarter, up 2.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.6% | +1.7 points |
| Q2 2026 | 4.6% | +128 points |
| Q1 2026 | 2.9% | +7 points |
| Q4 2025 | 5.3% | -2.8 points |
| Q3 2025 | 2.9% | +5.1 points |
| Q2 2025 | -123% | -123 points |
| Q1 2025 | -4% | -5.1 points |
| Q4 2024 | 8.1% | -1 points |
IART's operating margin was 4.6% last quarter, up 1.7 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over IART on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over IART on profitability, with a higher operating margin.
IART Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $85.7M | +233% |
| Q2 2026 | $10.5M | +$21.7M |
| Q1 2026 | -$5M | +$35.1M |
| Q4 2025 | -$5.4M | -126% |
| Q3 2025 | $25.8M | +$32.9M |
| Q2 2025 | -$11.2M | -205% |
| Q1 2025 | -$40.2M | -13907% |
| Q4 2024 | $21.1M | -38% |
IART's free cash flow has turned positive again: $86M over the past year, against −$5M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over IART on cash flow, with more consistent year-over-year improvement.
IART Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2020 | 3.0x | Elevated |
| Q1 2020 | 2.6x | Moderate |
| Q4 2019 | 3.3x | Elevated |
IART's net debt is about 3.0 years of its operating earnings (EBITDA).
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
IART Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 26.2 | Neutral |
IART's weekly RSI is 49 (neutral) and its Stochastic is 26 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
IART PE vs Healthcare Sector
| Metric | IART | Sector median | Relative |
|---|---|---|---|
| PE | 90x | 26x | 247% above |
| PE % | 89 | 29 | 60 pts above |
IART is trading at 90x earnings, a 247% premium to the Healthcare sector's median of 26x.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over IART on valuation relative to its sector.
IART Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.5 | 6.5% above |
| 20 week MA | $15.9 | 9.5% below |
| 50 week MA | $13.9 | 3.2% above |
| 100 week MA | $15.3 | 6.1% below |
| 200 week MA | $26.4 | 46% below |
IART's trend is mixed: it's above two of its five weekly moving averages, and 46% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over IART on trend strength, trading above more of its moving averages.
IART Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.7 | $66.4 | +13% |
| 2021 | $66.4 | $68.3 | +2.8% |
| 2022 | $68.3 | $56.3 | -18% |
| 2023 | $56.3 | $43.6 | -23% |
| 2024 | $43.6 | $22.3 | -49% |
| 2025 | $22.3 | $12.6 | -43% |
| 2026 YTD | $12.6 | $14.4 | +14% |
IART has finished four years in a row lower, and it's up 14% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over IART on returns for 2026, with the stronger performance.